Condition: Multiple Sclerosis · Sponsor: Centre Hospitalier Universitaire de Nīmes
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
This description comes directly from the study's public registry record.
Eric Thouvenot · +33.(0)4.66.68.32.61 · eric.thouvenot@chu-nimes.fr
Always discuss trial participation with your own doctor first.
| CHU d'Amiens | Amiens, France | Not Yet Recruiting |
| CHU de Besancon | Besançon, France | Not Yet Recruiting |
| CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| CHU de Caen | Caen, France | Not Yet Recruiting |
| CHU de Clermont Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| Hopital Henri Mondor | Créteil, France | Not Yet Recruiting |
| CHU de Dijon | Dijon, France | Not Yet Recruiting |
| CHU de Grenoble | Grenoble, France | Not Yet Recruiting |
| CHU de Lille | Lille, France | Not Yet Recruiting |
| CHU de Limoges | Limoges, France | Not Yet Recruiting |
| CHU de Lyon | Lyon, France | Not Yet Recruiting |
| Hopital Timone | Marseille, France | Not Yet Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03981003